Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 3/20 | 0.73 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | TYR | P14679 | 1/20 | 0.52 |
| ▸ | PLG | P00747 | 4/20 | 0.50 |
| ▸ | PLAU | P00749 | 4/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.50 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.50 |
| ▸ | KLK1 | P06870 | 1/20 | 0.50 |
| ▸ | F12 | P00748 | 1/20 | 0.48 |
| ▸ | AHR | P35869 | 3/20 | 0.47 |
| ▸ | CMA1 | P23946 | 1/20 | 0.47 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.46 |
| ▸ | F10 | P00742 | 1/20 | 0.46 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31656329 | 1.00 | F2 (0.73) | F2ENPP2KDM4EALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL6786736 | 0.98 | F2 (0.71) | F2ENPP2KDM4EALDH1A1HPGD | |
| SCHEMBL563181 | 0.85 | F2 (1.00) | F2PLGPLAUPRSS1KLKB1 | |
| Hydrochloric Acid SCHEMBL29688574 | 0.83 | F2 (0.52) | F2ENPP2KDM4EALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL7511443 | 0.82 | F2 (0.51) | F2ENPP2KDM4EALDH1A1HPGD | |
| SCHEMBL30201702 | 0.81 | ALDH1A1 (0.70) | F2ENPP2KDM4EALDH1A1HPGD | |
| SCHEMBL19608350 | 0.81 | ENPP2 (0.59) | F2ENPP2KDM4EALDH1A1HPGD | |
| SCHEMBL50552 | 0.81 | ALDH1A1 (0.70) | F2ENPP2KDM4EALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL8915608 | 0.79 | ALDH1A1 (0.68) | F2ENPP2KDM4EALDH1A1HPGD | |
| SCHEMBL29566955 | 0.79 | ALDH1A1 (0.68) | F2ENPP2KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110086877-A1 | Small Molecule Inhibitors of Botulinum Neurotoxins | BAVARI SINA | 2011-04-14 | — | — | US | claimed |
| US-7825154-B2 | Small molecule inhibitors of botulinum neurotoxins | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2010-11-02 | — | — | US | claimed |
| EP-1945209-A2 | BROAD SPECTRUM ANTIBACTERIAL COMPOUNDS | United States Government As Represented By The Secretary of The United States Army And The U.S. Army Medical Research & Materiel Command (US) | 2008-07-23 | — | — | EP | claimed |
| WO-2008041966-A2 | BROAD SPECTRUM ANTIBACTERIAL COMPOUNDS | UNITED STATES GOVERNMENT AS REPRESENTED BY THE SECRETARY OF THE UNITED STATES ARMY AND THE U.S. ARMY MEDICAL RESEARCH & MATERIEL COMMAND (US) | 2008-04-10 | — | — | WO | claimed |
| US-20070112048-A1 | Broad Spectrum Antibacterial Compounds | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND | 2007-05-17 | — | — | US | claimed |
| US-20070112049-A1 | nonpeptidic inhibitors of Botulinum neurotoxin A metalloprotease activity, such as 2-[4-(4-carbamimidoylphenoxy)phenyl]-1H-indole-5-carboximidamide, used for treating, inhibiting or preventing intoxication caused by bacteria | ARMY, UNITED STATES | 2007-05-17 | — | — | US | claimed |
| EP-0918768-A1 | AROMATIC AMIDINE DERIVATIVES USEFUL AS SELECTIVE THROMBIN INHIBITORS | C & C Research Laboratories (KR) | 1999-06-02 | — | — | EP | claimed |
| WO-1997045424-A1 | AROMATIC AMIDINE DERIVATIVES USEFUL AS SELECTIVE THROMBIN INHIBITORS | C & C RESEARCH LABORATORIES (KR) | 1997-12-04 | — | — | WO | claimed |
| EP-4615981-A1 | SYNTHETIC NUCLEIC ACIDS INCLUDING ASTROCYTE-DIRECTED PROMOTER CONSTRUCTS AND METHODS OF USING THE SAME | Eli Lilly and Company (US) | 2025-09-17 | — | — | EP | disclosed |
| WO-2024102961-A1 | SYNTHETIC NUCLEIC ACIDS INCLUDING ASTROCYTE-DIRECTED PROMOTER CONSTRUCTS AND METHODS OF USING THE SAME | ELI LILLY AND COMPANY (US) | 2024-05-16 | — | — | WO | disclosed |
| EP-4157261-A1 | CHROMANOL, QUINONE OR HYDROQUINONE COMPOUNDS FOR TREATMENT OF SEPSIS | Sulfateq B.V. (NL) | 2023-04-05 | — | — | EP | disclosed |
| US-20230050649-A1 | SPHINGOSINE KINASE INHIBITOR AMIDOXIME PRODRUGS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2023-02-16 | — | — | US | disclosed |
| US-11180489-B2 | Sphingosine kinase inhibitor amidoxime prodrugs | U niversity of Virginia Patent Foundation (US) | 2021-11-23 | — | — | US | disclosed |
| US-20200308159-A1 | SPHINGOSINE KINASE INHIBITOR AMIDOXIME PRODRUGS | SPHYNKX THERAPEUTICS, LLC | 2020-10-01 | — | — | US | disclosed |
| WO-2007072041-A1 | THERAPEUTIC COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-06-28 | — | — | WO | disclosed |
| US-20070112048-A1 | Broad Spectrum Antibacterial Compounds | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND | 2007-05-17 | — | — | US | disclosed |
| US-20070112049-A1 | nonpeptidic inhibitors of Botulinum neurotoxin A metalloprotease activity, such as 2-[4-(4-carbamimidoylphenoxy)phenyl]-1H-indole-5-carboximidamide, used for treating, inhibiting or preventing intoxication caused by bacteria | ARMY, UNITED STATES | 2007-05-17 | — | — | US | disclosed |
| CN-1312154-C | Purine derivatives as kinase inhibitors | LILLY CO ELI (US) | 2007-04-25 | — | — | CN | disclosed |
| EP-0918768-A1 | AROMATIC AMIDINE DERIVATIVES USEFUL AS SELECTIVE THROMBIN INHIBITORS | C & C Research Laboratories (KR) | 1999-06-02 | — | — | EP | disclosed |
| WO-1997045424-A1 | AROMATIC AMIDINE DERIVATIVES USEFUL AS SELECTIVE THROMBIN INHIBITORS | C & C RESEARCH LABORATORIES (KR) | 1997-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308159-A1 | SPHINGOSINE KINASE INHIBITOR AMIDOXIME PRODRUGS | SPHK1, SPHK2, S1PR2 | F2 731/4885ENPP2 29/4885KDM4E 1614/4885 |
| US-20070112048-A1 | Broad Spectrum Antibacterial Compounds | MPO, CAT, LPO | F2 2171/4885ENPP2 1712/4885KDM4E 3914/4885 |
| US-20230050649-A1 | SPHINGOSINE KINASE INHIBITOR AMIDOXIME PRODRUGS | SPHK1, SPHK2, S1PR2 | F2 731/4885ENPP2 29/4885KDM4E 1614/4885 |
| US-20070112049-A1 | nonpeptidic inhibitors of Botulinum neurotoxin A metalloprotease activity, such as 2-[4-(4-carbamimidoylphenoxy)phenyl]-1H-indole-5-carboximidamide, used for treating, inhibiting or preventing intoxication caused by bacteria | ACHE, CTRL, MMP2 | F2 578/4885ENPP2 340/4885KDM4E 1475/4885 |
| US-20110086877-A1 | Small Molecule Inhibitors of Botulinum Neurotoxins | ACHE, MMP2, TIMP3 | F2 521/4885ENPP2 279/4885KDM4E 3261/4885 |
| US-11180489-B2 | Sphingosine kinase inhibitor amidoxime prodrugs | SPHK1, SPHK2, S1PR2 | F2 731/4885ENPP2 29/4885KDM4E 1614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.